Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Weight loss and vascular inflammatory markers in overweight women with and without polycystic ovary syndrome.

Moran LJ, Noakes M, Wittert GA, Clifton PM, Norman RJ.

Reprod Biomed Online. 2012 Nov;25(5):500-3. doi: 10.1016/j.rbmo.2012.07.013. Epub 2012 Jul 26.

PMID:
22995747
2.

The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome.

Thomson RL, Brinkworth GD, Noakes M, Clifton PM, Norman RJ, Buckley JD.

Hum Reprod. 2012 Jul;27(7):2169-76. doi: 10.1093/humrep/des138. Epub 2012 May 2.

PMID:
22552687
3.

Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome.

Sales MF, Sóter MO, Candido AL, Fernandes AP, Oliveira FR, Ferreira AC, Sousa MO, Ferreira CN, Gomes KB.

Gynecol Endocrinol. 2013 Oct;29(10):936-9. doi: 10.3109/09513590.2013.819086. Epub 2013 Jul 30.

PMID:
23898913
4.

Vascular function in the diagnostic categories of polycystic ovary syndrome.

Moran LJ, Cameron JD, Strauss BJ, Teede HJ.

Hum Reprod. 2011 Aug;26(8):2192-9. doi: 10.1093/humrep/der159. Epub 2011 May 25.

PMID:
21616917
5.

Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.

Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D.

Hum Reprod. 2006 Jun;21(6):1426-31. Epub 2006 Feb 23.

PMID:
16497699
6.

Inflammatory and endothelial markers in women with polycystic ovary syndrome.

Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, Lekakis J, Panidis D.

Eur J Clin Invest. 2006 Oct;36(10):691-7.

PMID:
16968464
7.

A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.

Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ.

Clin Sci (Lond). 2009 May;116(10):761-70. doi: 10.1042/CS20080218.

PMID:
18851710
8.

Evidence of proatherogenic inflammation in polycystic ovary syndrome.

González F, Rote NS, Minium J, Kirwan JP.

Metabolism. 2009 Jul;58(7):954-62. doi: 10.1016/j.metabol.2009.02.022.

9.

Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.

Koiou E, Tziomalos K, Dinas K, Katsikis I, Kandaraki EA, Tsourdi E, Mavridis S, Panidis D.

Endocr J. 2012;59(1):21-9. Epub 2011 Oct 12.

10.

Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome.

Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, Makedos A, Chourdakis M, Tarlatzis BC.

Hum Reprod Update. 2011 Nov-Dec;17(6):741-60. doi: 10.1093/humupd/dmr025. Epub 2011 May 30.

PMID:
21628302
11.

Adipokines and soluble cell adhesion molecules in insulin resistant and non-insulin resistant women with polycystic ovary syndrome.

Koleva DI, Orbetzova MM, Nikolova JG, Tyutyundzhiev SB.

Arch Physiol Biochem. 2016 Oct;122(4):223-227. Epub 2016 May 31.

PMID:
27245110
12.

A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease.

Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL.

Clin Endocrinol (Oxf). 2014 Jun;80(6):843-9. doi: 10.1111/cen.12258. Epub 2013 Aug 26.

PMID:
23746214
13.

C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome.

Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ.

J Clin Endocrinol Metab. 2007 Aug;92(8):2944-51. Epub 2007 May 15.

PMID:
17504892
14.

Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).

Atiomo WU, Fox R, Condon JE, Shaw S, Friend J, Prentice AG, Wilkin TJ.

Clin Endocrinol (Oxf). 2000 Apr;52(4):487-92.

PMID:
10762292
15.

Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.

Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lönn M, Stener-Victorin E.

J Clin Endocrinol Metab. 2011 Apr;96(4):1068-76. doi: 10.1210/jc.2010-2279. Epub 2011 Jan 20.

PMID:
21252248
16.

Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity.

Cassar S, Teede HJ, Harrison CL, Joham AE, Moran LJ, Stepto NK.

Clin Endocrinol (Oxf). 2015 Jul;83(1):50-8. doi: 10.1111/cen.12619. Epub 2014 Nov 7.

PMID:
25262763
18.

Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.

Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A, Guzick DS, Hoeger KM.

J Clin Endocrinol Metab. 2008 Dec;93(12):4780-6. doi: 10.1210/jc.2008-1198. Epub 2008 Sep 23.

19.

The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome.

Moran LJ, Noakes M, Clifton PM, Norman RJ.

J Clin Endocrinol Metab. 2007 Oct;92(10):3796-802. Epub 2007 Jul 24.

PMID:
17652213
20.

Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.

Aziz M, Sidelmann JJ, Faber J, Wissing ML, Naver KV, Mikkelsen AL, Nilas L, Skouby SO.

Acta Obstet Gynecol Scand. 2015 Oct;94(10):1082-9. doi: 10.1111/aogs.12706. Epub 2015 Jul 18.

PMID:
26123797

Supplemental Content

Support Center